XML 32 R8.htm IDEA: XBRL DOCUMENT v3.20.4
Consolidated Statement of Cash Flows - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Cash Flows from Operating Activities      
Net income $ 7,082 $ 9,777 $ 6,193
Adjustments to reconcile net income to net cash provided by operating activities:      
Amortization 1,899 1,973 3,103
Depreciation 1,726 1,679 1,416
Intangible asset impairment charges 1,718 1,040 296
Charge for the acquisition of VelosBio Inc. 2,660 0 0
Charge for the acquisition of Peloton Therapeutics, Inc. 0 993 0
Charge for future payments related to collaboration license options 0 0 650
Deferred income taxes (668) (556) (509)
Share-based compensation 475 417 348
Other (49) 184 978
Net changes in assets and liabilities:      
Accounts receivable (1,002) 294 (418)
Inventories (855) (508) (911)
Trade accounts payable 724 399 230
Accrued and other current liabilities (1,138) 376 (341)
Income taxes payable 560 (2,359) 827
Noncurrent liabilities (453) (237) (266)
Other (2,426) (32) (674)
Net Cash Provided by Operating Activities 10,253 13,440 10,922
Cash Flows from Investing Activities      
Capital expenditures (4,684) (3,473) (2,615)
Purchase of Seagen Inc. common stock (1,000) 0 0
Purchases of securities and other investments (95) (3,202) (7,994)
Proceeds from sales of securities and other investments 2,812 8,622 15,252
Acquisition of VelosBio Inc., net of cash acquired (2,696) 0 0
Acquisition of ArQule, Inc., net of cash acquired (2,545) 0 0
Acquisition of Antelliq Corporation, net of cash acquired 0 (3,620) 0
Acquisition of Peloton Therapeutics, Inc., net of cash acquired 0 (1,040) 0
Other acquisitions, net of cash acquired (1,365) (294) (431)
Other 130 378 102
Net Cash (Used in) Provided by Investing Activities (9,443) (2,629) 4,314
Cash Flows from Financing Activities      
Net change in short-term borrowings 2,549 (3,710) 5,124
Payments on debt (1,957) 0 (4,287)
Proceeds from issuance of debt 4,419 4,958 0
Purchases of treasury stock (1,281) (4,780) (9,091)
Dividends paid to stockholders (6,215) (5,695) (5,172)
Proceeds from exercise of stock options 89 361 591
Other (436) 5 (325)
Net Cash Used in Financing Activities (2,832) (8,861) (13,160)
Effect of Exchange Rate Changes on Cash, Cash Equivalents and Restricted Cash 253 17 (205)
Net (Decrease) Increase in Cash, Cash Equivalents and Restricted Cash (1,769) 1,967 1,871
Cash, Cash Equivalents and Restricted Cash at Beginning of Year (includes $258 of restricted cash at January 1, 2020 included in Other Assets - see Note 6) 9,934 7,967 6,096
Cash, Cash Equivalents and Restricted Cash at End of Year (includes $103 of restricted cash at December 31, 2020 included in Other Assets - see Note 6) $ 8,165 $ 9,934 $ 7,967